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Summary 
Epstein-Barr virus (EBV) is an oncogenic herpesvirus that selectively infects and immortalizes 
human B lymphocytes. One determinant of this narrow tropism is human CR2, the only viral 
receptor within the superfamily of  proteins that contain short consensus repeats (SCRs). Human 
CR2 serves as a receptor for both C3dg and the gp350/220 glycoprotein of EBV, and binds 
the monoclonal antibody (mAb) OKB7, which blocks binding of both ligands to the receptor. 
In contrast, although murine CR2 is capable of binding human C3dg and this interaction can 
be blocked with the mAb 7G6, it does not bind OKB7 or EBV. We have determined the structural 
basis for absolute specificity of EBV for human CR2 through characterization  of a panel of 24 
human-murine chimeric receptors,  all of which bind human C3dg.  The results indicate that 
preferential binding of EBV to human CR2 is not due to unique amino acids that are capable 
of binding the virus, but reflects a distinct receptor conformation that can be achieved in murine 
CR2 with single amino acid substitutions in two discontinuous regions of the primary structure: 
replacement  of proline at position  15 with the corresponding serine from human CR2,  and 
elimination of a potential N-linked glycosylation site between SCR-1 and SCR-2. Furthermore, 
species-specific binding of EBV, OKB7, and 7G6 can all be manipulated through substitutions 
among residues 8-15,  suggesting that this octapeptide is part of a structural determinant that 
is critical for binding of both viral and natural ligands to CR2. 
V 
iral tropism is a multideterminant process whereby a par- 
ticular virus is able to bind, penetrate, replicate, and other- 
wise sustain its life cycle  within a restricted host. Several  tactics 
for such subterfuge involve the capacity of animal viruses both 
to evade as well as to exploit the host immune system. One 
of the best-described examples of a viral strategy to avoid neu- 
tralization  and permanent eradication by the humoral im- 
mune response is that of picornaviruses. Protomers that com- 
prise the protein coats of rhinovirus and poliovirus contain 
canyons with dimensions  such that they can potentially in- 
teract with loops from their respective receptors, although 
they are inaccessible to host neutralizing antibodies (1). Ex- 
ploitation of the host immune system, on the other hand, 
is a theme shared by several animal viruses, including HIV 
and rhinovirus, which bind CD4 (2, 3) and intercellular adhe- 
sion molecule 1 (ICAM-1) 1 (4,  5), respectively. 
EBV, a lymphocryptovirus, demonstrates narrow tropism 
1  Abbreviations  used in this paper: ICAM-1, intercellular  adhesion  molecule 
1; SCR, short consensus repeat. 
that indudes infection and effident immortalization of human 
B lymphocytes (6). EBV is also an oncogenic  herpesvirus that 
infects nearly all humans and is intimately involved in the 
pathogenesis  of Burkitt's lymphoma and other B cell lym- 
phomas that arise during states of impaired immune surveil- 
lance such as AIDS and post-transplant immunosuppression. 
Members of the family Hert~sviridae, such as EBV, have adopted 
a form of stealth in which they express only a small subset 
of viral genes after infection,  and in ways that are not en- 
tirely understood, avoid immune surveillance by establishing 
latency (7, 8). EBV also exploits the human immune system 
to gain entry to B cells. Preferential infection of human B 
lymphocytes by EBV appears to be multideterminant, and 
includes their unique capacity to bind the virus specifically 
via complement receptor type 2 (CR2;  CD21)  (9,  10). 
Human CR2 is a 145-kD transmembrane phosphoprotein 
that serves as a receptor for both the C3dg and iC3b proteins 
of the complement system (11), as well as for the gp350/220 
envelope glycoprotein of EBV  (12, 13). However, whereas 
CD4 (14), ICAM-1 (15, 16), and the poliovirus receptor (17) 
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it is the only viral receptor so far identified that is a member 
of the large family of proteins containing short consensus 
repeats (SCKs) (18, 19). The SCK is comprised of,o60 amino 
acids including four invariant cysteines that are disulfide bonded 
in a cys-1 to cys-3 and cys-2 to cys-4 pattern (20). This results 
in a three-dimensional structure consisting of a hydrophobic 
core surrounded by three B strands on one face and two 
strands on the other (21). The SCK motif has so far been 
identified in >30 mammalian proteins involved in the im- 
mune response,  inflammation, and tissue repair,  including 
the II-2 receptor (22), Endothelial leukocyte adhesion mole- 
cule 1 (23), and mouse lymph node homing receptor (24, 25). 
The extraceUular domain of human CK2 is comprised en- 
tirely of 15 or 16 SCKs that are the products of alternative 
splicing (26, 27), and it has been determined that SCK-1 and 
SCK-2 are both necessary and together sufficient to bind both 
gp350/220 and C3dg (28). In contrast, although murine CR2 
is also comprised of 15 SCKs (29-31)  and is able to bind not 
only murine C3dg, but also human C3dg, EBV is specific 
for the human receptor (32). This suggests that residues crit- 
ical for EBV binding might not be required for binding nat- 
ural ligand to the human receptor.  In addition, it presents 
a unique opportunity to define these distinct requirements 
and to identify the critical residues  that render human and 
murine B lymphocytes distinct in their capacity to bind EBV. 
Materials and Methods 
Isolation of  Murine CR2 eDNA.  Full-length  human CR2 cDNA 
was radiolabeled and used to probe a X gtl0 mouse spleen cDNA 
library (generously  provided  by Lloyd Klickstein, Center for Blood 
Research, Boston, MA) at high stringency. Seven positive plaques 
were identified among 106 screened. The DNA from each posi- 
tive clone was purified and used as a template in a PCK (33) in 
which  the  upstream primer  5'HMCK2.1  and the downstream 
primer 3'HMCK2.5 represented the 5' and 3' boundaries of SCR- 
1 and SCR-2 of mouse CR2, respectively. Amplification of four 
of the seven purified cDNA clones produced the expected 419-bp 
fragment and one of these, XMCK2.4, was cloned into the XmaI 
and XhoI sites of pBS KS + (Stratagene, La Jolla, CA) to produce 
pBS.MCK2.1. The nucleotide sequence of  both strands was deter- 
mined by the dideoxy method (34) and found to correspond ex- 
actly with that determined previously (29-31). 
Antibodies.  HB5  (IgG2a) and OKB7  (IgG2a) (Ortho Phar- 
maceuticals, Raritan, NJ) are mouse mAbs specific  for human CR2 
(10, 11). 7G6 (IgG2b) is a rat mAb that recognizes murine CR2 
(35). Murine mAb 9245 (IgG2a) (DuPont Co., Wilmington, DE) 
is specific  for the EBV gp350/220 envelope glycoprotein. KPCS.4 
(IgG2a) (American Type Culture Collection, Kockville, MD) is 
a mouse mAb that that was used as a nonspecific  control. Rabbit 
polyclonal anti-C3d serum A063 (Dako Corp., Carpinteria, CA), 
DTAF-conjugated goat F(ab')2 anti-mouse IgG, DTAF-conjugated 
goat anti-rat IgG (Jackson ImmunoResearch Laboratories, West 
Grove, PA), and FITC-conjugated goat F(ab')2 anti-rabbit  IgG 
(Accurate Chemical and Scientific,  Westbury, NY) were purchased. 
Immunofluorescence and Flow Cytometry.  48 h after transfection, 
COS cells were harvested  with PBS containing 0.5 mM EDTA and 
washed with PBS containing 0.1% BSA and 0.02% sodium azide. 
Replicate samples of cells from each transfection were assayed  for 
the capacity to bind HB5, OKB7, 7G6, C3dg, or EBV. Studies 
with HB5, OKB7, and 7G6 were performed by sequential incuba- 
tion with 4.0 #g/ml of the primary antibody followed  by 4.5 #g/ml 
DTAF-conjugated goat  F(ab')2 anti-mouse  IgG (for HB5  and 
OKB7) or 4.5 #g/ml DTAF-conjugated  goat anti-rat IgG (for 7G6). 
C3dg binding was determined  by sequential  incubation of  cells  with 
3/xg/ml pC3dg, followed  by 1:100 rabbit serum raised against 
human  C3d,  and  finally 1:100 FITC-conjugated  goat  F(ab')2 
anti-rabbit IgG. EBV binding was determined by resuspension of 
COS transfectants in 50 #1 purified EBV in RPMI followed by 
sequential incubation with 1.0 #g/ml anti-gp350, and 4.5 #g/ml 
DTAF-conjugated goat F(ab')~ anti-mouse  IgG. 
K562 stable transfectants were directly labeled with 7.0 #g/ml 
FITC-conjugated HBS, and sorted once with a FACStar  |  (Becton 
Dickinson & Co., Mountain View, CA) to obtain the brightest 
5-10%. These populations of K562 transfectants were expanded 
in cultures containing 200 #g/ml hygromyein B (Calbiochem- 
Behring Corp., San Diego, CA) and assayed for the capacity to 
bind HB5, OKB7, 7G6, and EBV in the same manner as described 
above for COS cells. 
Radioimmunoassays.  Polymerized  iC3b (piC3b) was radiolabeled 
to a specific activity of 106 cpm/#g with the iodobead method. 
Affinities for t~SI-p(iC3b) were determined by incubation of 5  x 
106 K562 transfectants at 0~  for 60 rain with increasing concen- 
trations of nSI-p(iC3b) in the presence or absence of OKB7 for 
CK2.H or 7G6 for CK2.M. Competition assays  were performed 
by incubation of 5  x  106 K562 transfectants at 0~  for 30 min 
with 10.0 #g/ml 7G6, OKB7, or KPCS.4, after which 3 #g/ml 
lzSI-p(iC3b) was added for an additional 60-rain incubation. Repli- 
cate samples for all KIAs were centrifuged through 0.3 ml of a 
3:1 mixture of dibutylphthalate/dinonylphthalate in 0.4-ml poly- 
propylene microfuge tubes for 30 s at 8,000 rpm at room tempera- 
ture. The tubes were cut, cell bound and free 12sI were determined, 
and the mean cpm was calculated for each replicate pair. 
Purification and Polymerization of Ligands.  Polymerized  C3dg 
(pC3dg) was prepared as described (28). Analysis  of pC3dg by su- 
crose gradient ultracentrifugation demonstrated an average molec- 
ular weight of 450,000, consistent with polymers ranging from 
tetramers to 20-mers. Purified C3b, factor H, and factor I were 
used to make iC3b, which was crosslinked with an 80-fold molar 
excess of glutaraldehyde for 2 h at room temperature, and then 
quenched with 1 M Tris-HC1, pH 7.5. Polymers were separated 
over gradients of 7.5-40% sucrose in PBS (wt/vol) centrifuged at 
200,000 g for 12 h at 4~  Fractions containing tetramers or larger 
polymers of polymerized iC3b (piC3b) were pooled, dialyzed, and 
stored in PBS at 0~  The B95-8 strain of EBV was prepared as 
described (36), and used as 1,000-fold concentrated culture super- 
natant in KPMI. 
Cell Lines and  Transfections.  COS  cells were maintained in 
DMEM with D-glucose  at 4,500 rag/liter supplemented  with 10% 
bovine calf serum (Hyclone Laboratories, Logan, UT) and 2 mM 
glutamine. K562 cells and Raji B lymphoblastoid cells (American 
Type Culture Collection) were grown in RPMI 1640 supplemented 
with 10% bovine calf serum and 2 mM glutamine. Plasmids were 
transfected  into COS cells for transient expression  using the DEAE- 
dextran procedure (37). Each of the plasmids encoding a chimeric 
CK2 cDNA was cotransfected with plasmid p141 (38) into K562 
cells through lipofection as described  previously (39). Stable trans- 
fectants were selected for and maintained in 200/xg/ml hygro- 
mycin B. 
Construction of Human-Murine Chimeric CR2 cDNA Fragments. 
Cassettes comprised of cDNA encoding SCK-1 and SCK-2 of 
human CK2, SCK-1 and SCK-2 of murine CR2, or two-SCK chi- 
meric fragments encoding a portion of each of these regions were 
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unique  XmaI and XhoI sites  at the 5' and 3' ends,  respectively. 
The cassette encoding SCR-1 and SCR-2 of human CR2 was created 
through  PCR  using  pi15  as  a  template  and  oligonucleotides 
5'HMCR2.2 and 3'HMCR2.3 (see Table 2) as upstream and down- 
stream primers, respectively. The cassette encoding SCR-1 and SCR- 
2 of murine CR2 was created in similar fashion as described above 
(isolation of routine CIL2 cDNA). 
The two-SCR chimeric fragments were created by taking ad- 
vantage of short stretches ofnucleotides that are conserved between 
human CR2  and murine CR2 within SCtL-1 and SCR-2.  This 
enabled design and synthesis of a panel of oligonucleotides for use 
in a two-step PCR strategy as follows (Tables 1 and 2). First, an 
upstream primer that adds a unique XmaI restriction site to the 
5' end of the fragment and a downstream primer that encodes sev- 
eral amino acids that are identical between the two species are used 
to amplify a segment of the first two SCRs of either human or 
murine CR2. The double-stranded product of this reaction is then 
used as an upstream primer together with a downstream primer 
that adds a unique XhoI restriction site to the 3' end of the frag- 
ment, now using CR2 cDNA from the other species as template 
in a PCR. The final product is a chimeric two-SCR fragment flanked 
by unique restriction sites. In some cases the template was neither 
wild-type human CR2 nor wild-type murine CR2, but rather one 
of the chimeric fragments (Table 2).  The nomenclature used for 
the chimeric fragments and for the constructs containing them con- 
sists of the prefix pi followed by a numerical designation,  which 
refers to the amino acids that are murine. The construct pi16-127 
was not created by PCK but rather was the product of a ligation 
between the 5' XmaI-SphI fragment of 16-127/Y and the 3' SphI- 
XhoI fragment of pi36-127.  The construct piPS was not created 
by PCR but rather was the product of a ligation between the 5' 
XmaI-SphI fragment of piPS/Y and the 3' SphI-XhoI fragment 
of pi36-127. 
Creation of  Expression Vectors.  Plasmid pi15 contains a full-length 
human CR2 cDNA within the eukaryotic expression vector CDM8 
(40).  Plasmid  piCK2.H  was  created  through  oligonucleotide- 
directed mutagenesis ofpil5 such that a silent G to C transversion 
was incorporated into the third position of a proline codon within 
the human CK2 leader peptide,  seven residues NH2 terminal to 
cysteine 1 of SCR-1. This resulted in creation of a unique XmaI 
restriction site located "~400 bp upstream from the unique XhoI 
restriction site already present in pi15, and facilitated unidirectional 
cloning of the 5'-XmaI- and 3'-XhoI-restricted two-SCR cassettes 
described above. The entire sequence of both strands of each insert 
was confirmed through  dideoxy sequencing. 
Table  1.  Oligonucleotides Used in  This Study 
Name  5'-3' Sequence 
5'HMCK2.1 
5'HMCK2.2 
5'HMCK2.3 
5'HMCK2.4 
5'HMCR2.5 
5'HMCR2.6 
5'HMCK2.7 
5'HMCK2.8 
5'HMCK2.9 
5'HMCK2.10 
3'HMCK2.1 
3'HMCK2.2 
3'HMCR2.3 
3'HMCK2.4 
3'HMCK2.5 
3'HMCK2.6 
3'HMCR2.7 
3'HMCR,2.8 
3'HMCR2.9 
3'HMCR2.10 
3'HMCR.2,11 
3'HMCK2.12 
3'HMCR2.13 
3'HMCR2.14 
GCACCCGGGGTCCTCGGGATTTCTTGTGACCCTCCTC 
GCACCCGGGGTCCTCGGGAT 
AATAAAACCATTTCTTGCTCAGATCCCATAGTACCAGG 
TCTAGAACTAGTGGATCCCC 
AGACATGGTGATTCTGTG 
GCTCCTCCTATATGTGAATATTTCAATAAA 
TGGGATAAACCTGCTCCTATATGTGAATCTGTGAATAAAACCATTTCTTGCTCA 
GATCCCATAGTACCAGGAGGA 
AATAAATATTCTTCTTGCTCAGATCCCATA 
TGGGATAAAGCTCCTCCTAAATGTGAATATTTCAATAAATATTCTTCTTGCCCT 
GAGCCCATAGTACCAGGGGGA 
GTGAATAAATATATTTCTTGC 
TTTTCTCCAATGAGGCGG 
TTTATTCACAGATTCACAT 
CCAACATTCTCACTTGTGTG 
ATCACCATGTCTGAATGGTGCCTTGGATCCTTTATTCATGAATCCCCCTGGTAC 
ACACTCGAGAGGGAAATCACTCTCACA 
AGAATAATAGGGTTTCCGAGCATTTTTGACTTCAGGAGGAG 
ACAGTTCCAGGAACTATGGGAAGAGAATAATA 
AATGAGGCGGTAGCTAGGTGAACAAGTGTACCTCAGAACAGTTCCA 
GCATTTTTGACAGGAGGAGGAGGGTC 
CGAGCATTTTTGATTTCAGGAGGAGG 
GGTTTCCGAGCATTTAGGACTTCAGGAGG 
GAATAATAGGGTTTCCGGCCATTTTTGACTTC 
GAATAATAGGGAATCCGAGCATTTTT 
AGAGAATAATAACTTTTCCGAGCATT 
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First PCR 
Chimera  5' Oligo  Y Oligo  Template  5' Oligo 
Second PCR 
3' Oligo  Template 
pi3-36  5'HMCR2.1  3'HMCR2.1  piCR2.M 
pi36-66  5'HMCR2.2  3'HMCR2.2  pi36-127 
pi66-74  5'HMCR2.3  YHMCR2.3  piCR2.H 
pi74-90  5'HMCR2.4  3'HMCR2.4  piCR2.H 
pi90-127  5'HMCR2.5  YHMCR2.5  pi36-127 
pi3-62  5'HMCR2.6  3'HMCR2.3  piCR2.H 
pi60-74  5'HMCR2.7  3'HMCR2.3  piCR2.H 
pi71-127  5'HMCR2.8  3'HMCR2.5  piCR2.M 
pi3-60/74-127  5'HMCR2.9  3'HMCR2.5  piCR2.M 
pi3-7  5'HMCR2.1  3'HMCR2.5  piCR2.H 
pi7-16  5'HMCR2.4  3'HMCR2.6  piCR2.H 
pi16-24  5'HMCR2.4  3'HMCR2.7  piCR2.H 
pi24-36  5'HMCR2.4  3'HMCR2.8  piCR2.H 
pi16-127  None  None  None 
pi3-127/Y  5'HMCR2.10  YHMCR2.5  piCR2.M 
pi16-127/Y  5'HMCR2.4  3'HMCR2.7  pi16-24 
piEP/Y  5'HMCR2.4  YHMCR2.9  piCR2.M 
piVI/Y  5'HMCR2.4  YHMCR2.10  piCR2.M 
piKL/Y  5'HMCR2.4  3'HMCR2.11  piCR2.M 
piAG/Y  5'HMCR2.4  YHMCR2.12  piCR2.M 
piKI/Y  5'HMCR2.4  3'HMCR2.13  piCR2.M 
piPS/Y  5'HMCR2.4  3'HMCR2.14  piCR2.M 
piPS  None  None  None 
PCR #1  YHMCR2.3  piCR2.H 
PCR #1  YHMCR2.3  piCR2.H 
5'HMCR2.2  PCR #1  piCR2.H 
PCR #1  YHMCR2.3  piCR2.H 
5'HMCR2.2  PCR #1  piCR2.H 
5'HMCR2.1  PCR #1  piCR2.M 
5'HMCR2.2  PCR #1  piCR2.H 
5'HMCR2.2  PCR #1  piCR2.H 
5'HMCR2.1  PCR #1  piCR2.M 
None  None  None 
PCR #1  YHMCR2.3  piCR2.H 
PCK #1  3'HMCR2.3  piCR2.H 
PCR #1  3'HMCR2.3  piCR2.H 
None  None  None 
5'HMCR2.1  PCR #1  piCR2.M 
PCR #1  3'HMCR2.5  pi3-127/Y 
PCR #1  3'HMCR2.5  pi3-127/Y 
PCR #1  3'HMCR2.5  pi3-127/Y 
PCR #1  3'HMCR2.5  pi3-127/Y 
PCR #1  3'HMCR2.5  pi3-127/Y 
PCR #1  3'HMCR2.5  pi3-127/Y 
PCR #1  3'HMCR2.5  pi3-127/Y 
None  None  None 
Results 
The Ligand Binding Site of Murine CR2 Is Located at the 
NH2 Terminus of the Receptor.  SCR-1 and SCR-2 of human 
CR2  have  the  same  affinity for both  human  C3dg  and 
gp350/220  as  does  the  entire  protein,  and  are  together 
sufficient to bind the mAb OKB7, which blocks binding of 
both ligands to the receptor (28).  We anticipated that the 
NH2-terminal pair of SCRs of murine CR2 would also be 
necessary and sufficient for binding human C3dg because the 
extracellular domains of both human and murine CR2 are 
comprised entirely of 15 SCRs, the amino acid sequences of 
these homologous proteins are 61% identical within the first 
two SCRs, and murine B lymphocytes are capable of  binding 
human C3dg (29-31).  This hypothesis was tested by sub- 
stituting a cDNA fragment encoding SCR-1 and SCR-2 of 
murine CR2 for sequence encoding the homologous pair of 
SCRs of human CR2 in the eukaryotic expression  vector 
piCR2.H (Fig.  1).  This resulted in creation of piCR2.M, 
in which amino adds from cysteine 1 of SCR-1 through cys- 
teine 4 of SCR-2 represent murine CR2, and the remainder 
Xma  I 
Xho I 
piCR2.H 
7588 bp 
Figure 1.  Expression  construct piCR2.H. Transcription  of wild-type 
full-length  human  CR2 is driven  by the CMV immediate  early  promoter, 
and the first two SCRs are flanked  by unique restriction sites such that 
they can be replaced with two-SCR cassettes encoding murine or chi- 
meric binding sites. 
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3-36  +  -  +  + 
38-66  +  +  -  + 
86-74  ~  +  -  -  + 
7440  +  +  -  + 
S10-127  I  +  +  -  + 
I  +  -  +  + 
71-127  +  +  -  + 
GO-?4  +  -  + 
34S0/74-127  -  +  + 
3-7  ~IB  +  +  -  + 
7-16  ~  +  -  +  + 
1824  ~  +  +  -  + 
24-36  ~  +  +  -  + 
16-127  +  -  4- 
3-127/Y  r  -  +  + 
lIF127/Y  r  +  4.  + 
Figure 2.  Binding  of ligands and mAbs to human-murine  chimeric mutants of CR2. Shown at the top are amino acid sequences of the first two 
SCRs of CR2.H (HUMAN) and CR2.M (MURINE) in which identical  residues are in bold and a single gap has been introduced  into the human 
sequence to maximize  alignment.  Below  are schematic  representations of the first two SCRs of human-murine  chimeric mutants in which the routine 
portion of each receptor is indicated  by a black bar. The numerical  designations  shown  on the far left indicate  the boundaries of the murine sequence 
within each chimeric fragment, in which the first and last (eighth) cysteine  residues are amino acids 3 and 127, respectively,  of the mature murine 
protein (the residues that define  the boundaries of each chimeric  substitution  are identical  between  the two species). Shown  to the right of  each construct 
are the results of immunofluorescence  analyses  of the capacity  of COS cells expressing each of the recombinant  receptors to bind the anti-human CR2 
mAb OKB7, the anti-murine  CR2 mAb 7G6, and the CR2 ligands pC3dg and EBV. Absence of binding indicates  no positives among  at least 2,000 
cells counted. A positive result indicates at least 10% brightly stained cells as determined  by fluorescence  microscopy. Wild-type  K562 cells do not 
specifically bind any of the antibodies or ligands. 
of upstream and downstream coding sequence is from human 
CR2. 
Receptors encoded by piCR2.H and piCR2.M were charac- 
terized through expression transiently in COS cells and stably 
in K562 cells. COS cells transfected with either piCR2.H 
or piCR2.M were assessed for their capacity to bind poly- 
merized human C3dg (pC3dg), EBV, and mAbs OKB7 (41) 
and 7G6 (35), which are specific for and block ligand binding 
to human CR2 (10) and murine CR2 (42), respectively. As 
predicted, indirect immunofluorescence demonstrated binding 
of human C3dg  to  COS  cells  bearing either CR2.H  or 
CR2.M,  whereas  EBV  and OKB7 were  specific for cells 
bearing human CR2, and 7G6 bound only to cells transfected 
with piCR2.M (Fig.  2). 
K562 stable transfectants bearing CR2.H or CR2.M were 
indirectly labeled with EBV, OKB7, or HB5 (which recog- 
nizes an epitope within SCR-3 and SCR-4 of human CR2) 
(28),  and analyzed by flow cytometry. Consistent with the 
results obtained by transient expression  in COS cells, K562 
cells bearing CR2.H bound EBV, OKB7, and HB5, whereas 
CR2.M transfectants stained only with HB5, which recog- 
nizes a human sequence that is COOH-terminal to the ligand 
binding site and common to both constructs (Fig. 3 and Table 
3).  These stable  transfectants were then used to determine 
the relative affinities of murine and human CR2 for human 
ligand. First, replicate samples ofK562 cells bearing CR2.H 
or CR2.M were incubated with 3/~g/ml 12SI-p(iC3b) in the 
presence of either OKB7 or 7G6, respectively.  As shown in 
Table 4,  both  CR2.H  and CR2.M bound human piC3b 
specifically, these interactions could be blocked with OKB7 
and 7G6, respectively,  and there was no cross-species reac- 
tivity of these antibodies. These findings were extended to 
a quantitative assessment of binding t2SI-p(iC3b) to the two 
receptors.  Replicate samples of K562 cells bearing CR2.H 
or CR2.M were incubated with incremental concentrations 
of 12SI-p(iC3b) in the presence or absence of OKB7 or 7G6, 
respectively,  after which bound and free ligand were sepa- 
rated by centrifugation through dibutyl/dinonylphthalate. 
Specific competition of the radiolabeled ligand with each 
species-specific antibody was observed (Fig. 4). Scatchard anal- 
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lines, and EBV and HB5 labeling of the clone specific to each panel are represented by solid and tightly spaced dotted lines, respectively. 
yses of the binding data indicated a threefold greater affinity 
of the human ligand for the human as compared with the 
murine binding site:/Ca =  2.16 nM (r  =  -0.99) and 6.78 
nM (r  =  -0.99)  for CR2.H and CR2.M,  respectively. 
Selective Binding of EBV to Human CR2 Results  from a Dis- 
tinct Receptor Conformation Rather than  from Residues Uniquely 
Capable of Binding Virus.  We next created a series of five 
constructs encoding receptors that contained chimeric ligand 
binding sites. Cysteine 1 of SCR-1 and cysteine 4 of SCR-2 
are residues  3 and 127, respectively,  of the mature murine 
protein, and the nomenclature used for the chimeric mutants 
indicates which of the amino acids are murine. Thus, mu- 
tants 3-36,  36-66,  66-74,  74-90,  and 90-127,  (Fig.  2) repre- 
sent chimeric receptors in which the substitutions are nonover- 
lapping and span the entire ligand binding site. These five 
chimeric receptors  were transfected into COS cells and as- 
sayed for the capacity to bind human pC3dg, EBV, OKB7, 
and 7G6. The capacity of both murine and human CR2 to 
bind human pC3dg led us to anticipate that human-murine 
chimeric binding domains would also bind human pC3dg, 
and this proved to be a correct assumption. Surprisingly, not 
only did all five of the chimeric receptors  bind pC3dg, but 
they also bound EBV specifically (Fig. 2). These observations 
were confirmed through stable expression of these constructs 
in K562 cells (Fig.  3; Tables 3 and 4).  This suggested that 
differential binding of EBV  to human and murine CR2 is 
not simply due to residues  in the human receptor that are 
uniquely capable of binding EBV, but rather is the result of 
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K562 Cell Transfectants 
Mean fluorescence 
Cell line  HB5  OKB7  EBV 
K562WT  9  10  10 
RAJI  144  135  96 
CR2.H  183  205  192 
CR2.M  91  8  10 
Chimeras 
3-36  91  5  88 
36-66  79  77  105 
66-74  152  7  128 
74-90  194  145  92 
90-127  144  149  146 
3-62  92  6  65 
60-74  59  5  89 
71-127  128  123  68 
3-60/74-127  77  7  14 
3-7  64  64  86 
7-16  144  8  126 
16-24  164  196  110 
24-36  253  261  95 
16-127  83  5  48 
3-127/Y  115  9  30 
16-127/Y  112  48  97 
conformational differences between the two receptors  that 
arise from nonlinear substitutions. In contrast, specific linear 
sequences were found to be critical for binding OKB7 and 
7G6.  Two of the chimeric  receptors  (3-36, which contains 
16 amino acids that are unique to murine CK2, and 66-74, 
which has four residues unique to the mouse receptor) failed 
to bind OKB7. Not only did the NH2-terminal transfer  of 
residues from the mouse to human receptor in mutant 3-36 
result  in loss of OKB7 binding, but it also created  a 7G6 
epitope and was the only substitution among these five to 
do so. 
Four additional  chimeric  receptors  were created  and ex- 
pressed in COS cells and K562 cells to determine if more 
extensive substitutions of murine for human sequence would 
eliminate  the capacity  to bind EBV. Chimeric receptors  in 
which SCR-1 (3-62), SCR-2 (71-127), or the inter-SCR linker 
(60-74) of human CR2 were replaced with homologous mu- 
fine sequence were still capable of binding EBV. Simultaneous 
substitution of both SCR-1 and SCR-2 of human CR2 with 
those from mouse while maintaining  a human inter-SCR 
linker  (3-60/74-127)  did eliminate  EBV binding,  although 
this  mutant still bound pC3dg and piC3b. The pattern of 
OKB7 and 7G6 binding to these four mutants was consis- 
tent with that observed among the first set of five chimeras 
described above. The receptor in this panel of four that did 
bind OKB7 was 71-127, which maintains  human residues 
within the NH2-terminal and inter-SCR regions  that were 
determined to be critical by mutants 3-36 and 66-74, respec- 
tively. Similarly, mutants 3-62 and 3-60/74-127  contain mu- 
fine residues between positions 3 and 36 and,  like mutant 
3-36,  they reconstitute a 7G6 epitope. 
Single Amino Acid Substitutions within Two Discontinuous 
Regions Render Murine CR2 Capable of Binding EBV.  We 
could not eliminate  EBV binding to human CR2 through 
simple substitution of a limited linear portion of the ligand 
binding site with murine residues. However, identification 
of amino acids within two discrete regions that were required 
for species-specific binding of mAbs that effectively blocked 
receptor-ligand interaction suggested that these regions might 
also account for the preferential binding of EBV to human 
CR2. Therefore,  additional constructs were created in an at- 
tempt to define further the amino acids critical to the OKB7 
and  7G6 epitopes. 
The NH2-terminal region demonstrated by chimera 3-36 
to be important for binding both OKB7 and 7G6 was dis- 
sected through construction of four additional mutants: 3-7, 
7-16, 16-24, and 24-36, which were expressed transiently  in 
COS cells and stably in K562 calls, and assayed for the ca- 
pacity to bind EBV, pC3dg, HB5, OKB7, and 7G6 (Figs. 
2 and 3; Tables 3 and 4). All four mutants bound EBV, pC3dg, 
and HB5 as expected, however, only one of them, 7-16, resulted 
in elimination  of OKB7 binding and acquisition  of a 7G6 
epitope.  This chimeric  receptor consists  entirely  of human 
CR2 sequence except for the six nonconservative  substitu- 
tions contained  within the mouse segment EVKNARKP, 
which replaces the human residues PILNGRIS. 
Collectively,  these  studies  indicated  that it was possible 
to create a 7G6 epitope while destroying the OKB7 epitope 
of human CR2 through substitution of six amino acids with 
residues unique to mouse CR2 in these same positions.  We 
next asked whether substitution of this same region of mu- 
fine CR2 with human sequence would produce the opposite 
result,  namely replacement  of the 7G6 epitope with a ca- 
pacity to bind OKB7. This was studied through creation and 
characterization of three additional mutants:  16-127, 3-127/Y, 
and  16-127/Y (Fig.  2). 
Chimera 16-127  encodes SCR-1 and SCR-2 of murine CR2, 
except for eight amino acids unique to human CR2 at its 
extreme NH2 terminus.  As expected, this resulted in loss of 
7G6 binding. However, this substitution with human residues 
was not sufficient to create an OKB7 epitope,  which was 
also consistent with the earlier findings that chimeras 66-74 
and 60-74 resulted in loss of OKB7 binding. These two mu- 
tants share four residues unique to murine CR2. We predicted 
that the substitution of threonine for tyrosine in the linker 
between SCR-1 and SCR-2 would be more significant be- 
cause this is the third position of a potential N-linked glycosy- 
lation site in the mouse receptor (NKT), which is absent in 
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Binding K562  Transfectants 
12sI piC3b (percent Bound) 
Cell line  RPC5.4  7G6  OKB7 
K562 WT  1  1  1 
CR.2.H  51  52  7 
CR.2.M  27  1  27 
Chimeras 
3-36  36  1  36 
36-66  21  17  2 
66-74  51  50  52 
74-90  39  35  2 
90-127  48  45  9 
3-62  41  2  41 
60-74  17  15  17 
71-127  30  27  2 
3-60/74-127  12  1  12 
3-7  44  41  10 
7-16  27  1  27 
16-24  49  47  6 
24-36  67  65  32 
16-127  22  19  22 
3-127/Y  29  1  28 
16-127/Y  31  27  17 
Wild-type K562  cells,  K562  cells bearing recombinant human CR2 
(CR2.H),  K562 cells bearing the murine CK2 ligand binding site on 
a human CR.2 backbone (CR2.M), or K562 cells bearing chimeric recep- 
tors were incubated with 3 #g/ml lzSI-p(iC3b)  in the presence of saturat- 
ing concentrations of either anti-human CR2 (OKB7), anti-murine  CR2 
(7G6),  or subclass-matched nonspecific mAb RPC5.4. 
human CK2 (NKY). Therefore, chimeric receptor 3-127/Y 
was created, which eliminates the potential for glycosylation 
in the mouse receptor. This mutant retained the ligand and 
mAb binding profile of murine CR2.  However, when this 
single amino acid substitution at position 68 was combined 
with the NH2-terminal changes present in mutant  16-127 
through construction of mutant  16-127/Y,  an OKB7 epi- 
tope was created (Fig.  2). 
It was apparent from studies of K562 cells bearing receptor 
16-127/Y  that its affinity for OKB7 was less than that of 
wild-type human CR2 (Tables 3 and 4). However, this was 
our initial indication that the first inter-cysteine segment and 
the first inter-SCR linker were together critical in forming 
a functional domain. This notion was confirmed through 
studies of EBV binding to these same three mutants. 
As indicated in Fig.  2,  COS cells transfected with con- 
struct pi16-127 were clearly positive when examined for the 
capacity to bind both pC3dg and EBV. However, when this 
chimera was expressed stably in K562 ceils, only some of the 
cells were capable of binding EBV. As shown in Table 3, the 
mean  fluorescence of  16-127 cells  labded  with  EBV  is 
significantly greater than those values obtained with K562 
wild-type cells and K562 cells bearing CR2.M.  However, 
it is apparent from the histogram overlay of clone 16-127 in 
Fig. 3 that only a subset of these cells are positive although 
they all bind HB5. This is in contrast with most of the other 
EBV-binding clones in which the EBV histogram overlays 
the HB5 histogram. The 16-127 cells that appear as a shoulder 
on the EBV histogram in Fig. 3 are presumably those bearing 
the most receptors, which suggests that this chimera has a 
diminished capacity to bind EBV as compared with wild- 
type human CR2.  This argument could also be made for 
clones 74-90 and 24-36, in which the EBV histogram is clearly 
positive but was reprodudbly shifted to the left of the HB5 
histogram. In contrast, EBV binding to K562 cells bearing 
receptor 16-127/Y was comparable to binding of liB5 to these 
same cells (Table 3; Fig. 3). Therefore, as was observed with 
OKB7, although the single substitution of tyrosine for threo- 
nine at position 68 between SCR-1 and SCR-2 had no effect 
by itself on the capacity of the murine receptor to bind EBV, 
when combined with human sequence between cysteine 1 
and cysteine 2 of SCR-1,  a viral binding site was created. 
Further identification of the residue(s) between cysteine 
1 and cysteine 2 of SCR-1 that were critical for differential 
binding of EBV, OKBT, and 7G6 to human CR2 and mu- 
rine CR2 was achieved through creation and characteriza- 
tion of six additional chimeric receptors: EP/Y, VI/Y, KL/Y, 
AG/Y,  KI/Y,  and PS/Y (Table 5).  All of these constructs 
contain SCR-1 and SCR-2 of murine CK2 with a substitu- 
tion of tyrosine from human CR2 at position 68.  In addi- 
tion, each mutant contains a single amino acid from human 
CR2 between positions 8 and 15 inclusive. These constructs 
were transfected transiently into COS cells and assayed for 
the capacity to bind C3dg, EBV, 7G6, and OKB7 (Table 5). 
All six of the receptors were properly expressed as demon- 
strated by their capacity to bind C3dg. The results further 
demonstrate that substitution of a human serine for a mu- 
rine proline at position 15 is sufficient to confer the capacity 
to bind EBV and it is the only substitution among these to 
do so. In addition, the single substitution of a human isoleu- 
cine for a murine lysine at position 14 is the only mutation 
that results in loss of the 7G6 epitope. Alternatively, although 
replacement of the human CR2 segment from amino acids 
8-15 with murine residues results in loss of the OKB7 epi- 
tope (chimera 7-16), no single human for a murine substitu- 
tion  within  this  fragment  is  suffident  to  restore  OKB7 
binding. 
Finally,  the contribution of the human tyrosine residue 
at position 68 was assessed through creation and character- 
ization of chimera PS, which differs from chimera PS/Y in 
that position 68 is the threonine from murine CR2. The results 
demonstrate that the serine for proline substitution results 
in the capacity to bind EBV regardless of whether a tyrosine 
or threonine is present at position 68. These findings are con- 
sistent with those described above, in which both chimeras 
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Figure  4.  Saturation  binding  of 12SI-p(iC3b) to 
K562 cells bearing recombinant human CR2 (CR2.H) 
or murine CR2 (CR2.M) ligand binding sites. K562 
cells bearing CR2.H were incubated with incremental 
concentrations  of 12SI-p(iC3b) in the presence or ab- 
sence of 10/zg/ml OKB7 (A), and K562 cells bearing 
CR2.M were incubated with incremental  concentra- 
tions of 12SI-p(iC3b) in the presence or absence of 10 
~g/ml 7G6 (B). Cell-bound tzSI-p(iC3b) was deter- 
mined in replicate samples. Nonspecific binding (open 
circles) was subtracted  from binding in the absence of 
inhibiting  antibody  (open squares) to yidd  specific 
binding (filled circles). Lines represent the least squares 
fit of all data points that are the means of replicate 
determinations.  Scatchard analyses of ]igand binding 
to CR2.H (C) and CR2.M (D) are shown below. 
16-127  and  16-127/Y  were capable  of binding  EBV  when 
expressed  on  COS  cells. 
Discussion 
The  narrow  tropism  of EBV  is  currently  a  unique  ex- 
perimental system for several reasons.  First, EBV is the only 
herpesvirus with a single predominant membrane glycopro- 
tein, and the only herpesvirus for which the viral ligand and 
its host  receptor have been defined biochemically.  It is this 
NH 2 
Figure S.  Schematic representation  of the short consensus repeat three- 
dimensional structure.  Shown above is the three-dimensional  structure  of 
SCIk-16 from factor H  (21) in which a hydrophobic  core is surrounded 
by three B strands on one face and two ~  strands  on the other.  Shown 
below is the same structure on which we have indicated the positions of 
the four invariant cysteines, the location of the loop that contains amino 
acids 8-15, which correspond  to amino acids PlLNGtLIS of human CP-,2, 
and the location of F37 of factor H, which corresponds  to F35 of human 
CR2. 
Table  5.  Binding of mAbs and Ligands  to Chimeric CR2 
Point Mutants 
Amino acid 
sequence 
Construct  8-15  68  EBV  OKB7  7G6  C3dg 
CR2.H  PILNGRIS  Y  +  +  -  + 
CR2.M  EVKNARKP  T  -  -  +  + 
EP/Y  PVKNARKP  Y  -  -  +  + 
VI/Y  EIKNAtLKP  Y  -  -  +  + 
KL/Y  EVLNARKP  Y  -  -  +  + 
AG/Y  EVKNGRKP  Y  -  -  +  + 
KI/Y  EVKNARIP  Y  -  -  -  + 
PS/Y  EVKNARKS  Y  +  -  +  + 
PS  EVKNARKS  T  +  -  +  + 
1307  Martin et al. envelope glycoprotein,  gp350/220,  that contains the NH2- 
terminal sequence EDPGFFNVE, which has been shown to 
be the primary CR2 binding site for EBV and corresponds 
to the sequence EDPGKQLYNVE of human C3dg (43, 44). 
Second,  whereas  poliovirus,  rhinovirus,  and HIV exploit 
receptors of the Ig superfamily, EBV, through its specific  in- 
teraction with CR2, is the only virus known to gain intra- 
cellular access through a member of the SCR family of pro- 
teins. Third, murine CR2 is the only known example of a 
viral receptor homologue that binds the heterologous  nat- 
ural ligand but not the virus. 
This absolute specificity of EBV and OKB7 for human 
CR2 and of 7G6 for murine CR2, yet comparable affinities 
of human iC3b and C3dg for both receptors, was fundamental 
to the strategy used in this study. Our major concern when 
designing these experiments was that failure of a particular 
mutant to bind EBV might not be due to substitution of 
residues critical for direct ligand contact or even disruption 
of a critical epitope but rather the result of a more general 
disruption of protein conformation. We have demonstrated 
previously that both SCR-1 and SCR-2 of human CR2 are 
required and sufficient to bind EBV and C3dg (28). This ob- 
servation,  together with the known capacity of routine B 
lymphocytes to bind human C3dg, suggested that it would 
be possible to construct and characterize a panel of human- 
murine CR2 chimeras where only some would bind EBV 
but where all would bind C3dg, thus ensuring that the SCR 
conformation was maintained. This strategy was also regarded 
as preferable to an approach based upon peptides because of 
our anticipation that discontinuous portions of the linear se- 
quence might contribute to the ligand binding site(s), as well 
as our concern that a proper pattern of disulfide bonds would 
be critical to the native SCR conformation. Therefore,  24 
human-murine CR2 chimeras were created and characterized 
for their capacity to bind EBV, human C3dg and iC3b, OKB7, 
7G6,  and HB5  in an attempt to determine if the require- 
ments for binding natural and viral ligands to human CR2 
are separable, and to identify the structural basis for preferential 
binding of EBV to the human receptor. 
The findings reported here demonstrate that species-specific 
epitopes within human CR2 and murine CR2 are based upon 
critical linear as well as nonlinear determinants,  and the ca- 
pacities of these receptors to bind EBV, OKB7, and 7G6 are 
all influenced by substitutions  within the same NH2-ter- 
minal peptide. Specifically,  replacement of the sequence EV- 
KNARKP between cys-1 and cys-2 of the first SCR of mu- 
fine CR2 with the corresponding peptide PILNGRIS from 
human Clk2 eliminates the 7G6 epitope. In addition,  when 
this NH2-terminal  sequence is combined with elimination 
of a potential  N-linked glycosylation site (NKT) between 
SCR-1 and SCR-2 of murine CR2, epitopes for both EBV 
and OKB7 are created. The epitopes for OKB7 and 7G6 are, 
in fact, mutually exclusive, and the structural requirements 
for binding C3dg, EBV, and OKB7 to human CR2 are dis- 
tinct and separable. Finally, any region of murine CR2, in- 
cluding the entire first or second SCR, can substitute for the 
corresponding region of human CR2 with retention of the 
capacity to bind EBV. These observations indicate that this 
NH2-terminal  peptide  may  well  bind  OKB7  and  7G6 
directly, but it cannot represent a site of unique contact for 
EBV on the human receptor since it can be replaced with 
routine sequence without disturbing this interaction.  It is 
more likely that when human sequence in this region is in- 
corporated into the murine receptor, it results in a confor- 
mational change that allows the virus access to critical residues 
involved in direct  ligand  contact.  Presumably, the human 
receptor is able to accommodate murine sequence in this re- 
gion and still bind EBV because of a nonlinear portion of 
the receptor that differs in the murine homologue. 
Substitution of eight residues at the NH2 terminus of mu- 
rine CR2 with the corresponding amino acids from human 
CIL2 (chimera 16-127) rendered COS cells  bearing this receptor 
capable of binding EBV. In fact, a single replacement of pro- 
line with serine at position  15 was sufficient to accomplish 
this. However, only some of the K562 cells bearing receptor 
16-127 were capable of  binding EBV. An additional substitu- 
tion at position 68 was required, as demonstrated by the ca- 
pacity of all K562 cells bearing receptor  16-127/Y to bind 
the virus. There are at least two possible explanations for 
this discrepancy. First, the level of receptor expressed tran- 
siently on COS cells was consistently several-fold  greater than 
that observed on stable K562 transfectants as determined by 
indirect immunofluorescence.  Therefore, the COS cells  bearing 
receptor 16-127 could correspond  to those observed in the 
shoulder of the 16-127 histogram of K562 cells (Fig. 3). A 
second possibility is that the NKT consensus sequence be- 
tween SCR-1 and SCR-2 of murine CR2 is glycosylated in 
K562 cells but not in COS cells. In fact, the finding that 
only some of the K562 cells bearing receptor 16-127 can bind 
EBV could reflect differential glycosylation of this site among 
this population  of K562 cells. A definitive explanation for 
this  discrepancy will require  complementary biosynthetic 
studies. 
Although the three-dimensional structure of CR2 has not 
yet been determined, the tertiary structure of SCR-16 from 
human complement factor H has been solved through high 
field two-dimensional nuclear magnetic resonance  spectroscopy 
(21). As shown in Fig. 5, the SCR structure is based upon 
a/3 sandwich in which the NH2 and COOH termini are 
at opposite ends of the module. One face consists of three 
strands, the other face  is formed from two 3 strands, and 
the regions joining the B strands are comprised of weU-defined 
turns and less well-defined loops. The two faces contribute 
highly conserved side chains to form a globular compact hy- 
drophobic core. Alignment of the >140 SCR sequences avail- 
able from ~>20 proteins indicates that the most highly con- 
served residues are found in regions with critical structural 
importance while the more variable positions are located in 
the less well-defined loops. On this basis, it has been predicted 
that the general structure determined for SCR-16 of factor 
H will be shared by other SCR-containing proteins (21). Based 
upon this assumption, the structural significance  of our func- 
tional data derived from mutagenesis of the ligand binding 
domain of CR.2 becomes apparent. 
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His 13, are semi-conserved and highly solvent exposed, yet 
play no demonstrable role in stabilizing the tertiary struc- 
ture of the single SCK. These observations, together with 
the determination that they are located in adjacent positions 
within  the tertiary structure and reside proximate to  the 
COOH terminus, suggest that they might participate in in- 
teractions between SCILs, and are consistent with our findings 
in this study (Fig. 5). Amino acids 8-15, which we find to 
be structurally critical to converting several functional epi- 
topes between murine and human CR2, correspond to residues 
10-17 of SCK 16 of factor H (because of two additional amino 
acids before cysteine 1 in factor H), which include His-13. 
In addition, Phe 37 of SCK-16 of factor H  corresponds to 
Phe 35 of SCK-1 of human CK2, which is replaced by tyro- 
sine in mutant  24-36.  As shown in  Fig.  3,  this chimeric 
receptor appears to have a diminished capacity to bind EBV. 
Furthermore, our finding, that preferential binding of EBV 
to human CK2 is based at least in part on critical substitu- 
tions among residues 8-15 combined with changes in the inter- 
SCK sequence, is supported by the fact that these two regions 
are proximate in the tertiary SCK structure,  Finally, high 
local mobility of residues 17-22 within SCK-16 of factor H, 
combined with observations that the sequence in this region 
tends to be nonconserved among SCRs and includes large 
insertions, suggests a functional domain (21). Position 17 in 
this sequence corresponds with a human serine versus a mu- 
fine proline in position 15 of CK2, a substitution that could 
easily distort this potentially functional loop, and was alone 
sufficient to render COS cells bearing receptor PS capable 
of binding EBV. This same loop within SCR-2 of human 
CR2 is replaced by routine sequence in the chimera 74-90 
(Fig.  2), which also appears  to have a reduced capacity to 
bind EBV when expressed on K562 cells as determined by 
the location of the EBV histogram to the left of that for HB5 
(Fig.  3). 
In summary, the findings reported here are consistent with 
functional predictions based upon the SCR consensus struc- 
ture proposed by Norman et al. (21). Specifically, the peptide 
PILNGRIS of human CR2, particularly the serine at posi- 
tion 15, might be critical for proper alignment of SCR-1 and 
SCR-2 with respect to one another and is likely to be respon- 
sible for the distinct receptor conformation required to bind 
EBV. In addition, the inter-SCR region appears to be proxi- 
mate to and perhaps a part of this functional domain, and 
glycosylation of this region in murine CR2 may contribute 
to its lack of affnity for EBV. Further characterization of 
the significance of these critical amino acid substitutions, such 
as whether they represent sites of direct ligand contact, lead 
to local disruption of species-specific  epitopes, or alter the 
three-dimensional alignment of SCR-1 and SCR-2 relative 
to one another, will require complementary structural anal- 
yses of CR2, such as two-dimensional nuclear magnetic res- 
onance and crystallography. 
Finally,  we have demonstrated that the requirements for 
binding EBV and C3dg to human CR2 are separable. Thus, 
although the viral and natural ligand binding sites overlap, 
the human receptor should be mutable so as to avoid the virus 
while maintaining normal function. This observation at least 
suggests the possibility that the capacity to support EBV in- 
fection is somehow an advantage shared by humans. 
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